Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen

Clinical Transplantation

Volumn 27, Issue 3, 2013, Pages 455-462

  Kamar, Nassim ^a,b,c   Del Bello, Arnaud ^a,b   Congy Jolivet, Nicolas ^a,b   Guilbeau Frugier, Céline ^a,b   Cardeau Desangles, Isabelle ^a   Fort, Marylise ^a   Esposito, Laure ^a   Guitard, Joelle ^a   Gamé, Xavier ^a   Rostaing, Lionel ^a,b,c  

^a CHU RANGUEIL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c CHU PURPAN   (France)

Author keywords

Donor specific antibodies; Everolimus; Humoral rejection; Kidney transplantation

Indexed keywords

BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; TACROLIMUS; ALLOANTIBODY; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ADULT; ANTIBODY MEDIATED REJECTION; ANTIBODY SPECIFICITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DONOR; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; FRANCE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MIDDLE AGED; PROGNOSIS; RISK FACTOR;

CALCINEURIN INHIBITORS; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; FRANCE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS; TISSUE DONORS;

EID: 84878644009     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12127     Document Type: Article

References (18)

1. Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011: 378: 1428.
2. Lefaucheur C, Loupy A, Hill GS et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010: 21: 1398.
3. Cosio FG, Gloor JM, Sethi S, Stegall MD. Transplant glomerulopathy. Am J Transplant 2008: 8: 492.
4. Everly MJ, Everly JJ, Arend LJ et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009: 9: 1063.
5. Guba M, Pratschke J, Hugo C et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplantation 2010: 90: 175.
6. Weir MR, Mulgaonkar S, Chan L et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int 2010: 79: 897.
7. Lebranchu Y, Thierry A, Thervet E et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study. Am J Transplant 2011: 11: 1665.
8. Schena FP, Pascoe MD, Alberu J et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009: 87: 233.
9. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006: 17: 581.
10. Budde K, Becker T, Arns W et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011: 377: 837.
11. Liefeldt L, Brakemeier S, Glander P et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012a: 12: 1192.
12. Sis B, Mengel M, Haas M et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010: 10: 464.
13. Tedesco Silva H Jr, Cibrik D, Johnston T et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010: 10: 1401.
14. Holdaas H, Rostaing L, Seron D et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation 2011: 92: 410.
15. Lebranchu Y, Toupance O, Touchard G et al. Impact of early conversion at 3 months from cyclosporine (CsA) to sirolimus (SRL) in association with mycophenolate mofetil (MMF) on renal function - "results at 48 months of follow up of a multicenter randomized controlled trial: the concept study. Am J Transplant 2010: 10(S4): 151.
16. Pascual J, Arns W. Does everolimus increase donor-specific HLA antibodies in kidney transplant recipients? Am J Transplant 2012: 12: 2561.
17. Liefeldt L, Glander P, Brakemeier S, Budde K. Immunosuppressive potential and side effects of everolimus. Am J Transplant 2012b: 12: 2563.
18. Pinsky BW, Takemoto SK, Lentine KL, Burroughs TE, Schnitzler MA, Salvalaggio PR. Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression. Am J Transplant 2009: 9: 2597.